【SOLUTN 0093 交流专区】方案工程

icy97

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-24092020-00001
Subject	REGISTRATION, MANUFACTURING AND COMMERCIALISATION AGREEMENT BETWEEN SOLUTION GROUP BERHAD ("SGB" OR "COMPANY") AND CANSINO BIOLOGICS INC. ("AGREEMENT")
Description	Reply to Query
Query Letter Contents	We refer to your Company’s announcement dated 23 September 2020, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- 1) The tenure of the Agreement. 2) The expected date of registration with the National Pharmaceutical Regulatory Agency.
The Company wishes to provide the following additional information: 1) The tenure of the Agreement is 5 years. 2) The expected date of registration with the National Pharmaceutical Regulatory Agency is expected to take about 6 months from now. This announcement is dated 24 September 2020.

Type	Announcement
Subject	OTHERS
Description	SOLUTION GROUP BERHAD ("SGB" or "THE COMPANY")  LETTER OF AUTHORISATION FROM CANSINO BIOLOGICS INC. ("CanSino")
We refer to the Company’s announcements dated 19 August 2020, 24 August 2020, 27 August 2020, 2 September 2020, 23 September 2020 and 24 September 2020.  The Board of Directors of Solution Group Berhad (“Board”) wishes to announce that our subsidiary, Solution Biologics Sdn Bhd (“SOLBIO”), had on 30 October 2020 received a Letter of Authorisation (“LOA”) from CanSino Biologics Inc. (“CanSino”, SHSE: 688185, HKEX:06185). CanSino has authorized SOLBIO to develop the business in Philippines, Vietnam, Thailand, Myanmar, Cambodia, Laos and Brunei (“Territory”), for their Recombinant Novel Coronavirus Vaccine candidate (Ad5-nCoV) composed of an adenovirus type 5 vector (Bulk Product presentation) (“Bulk Product”), by working with the respective local partners, authorities and regulatory bodies in the Territory in order to prepare the market for the Bulk Product, so that the Product can be sold when it is approved. Eventually, Malaysia will be the regional fill and finish hub for CanSino and supply the finished product to the Territory. The LOA is valid for six (6) months with effective from 28 October 2020. We attach a copy of the Company's Press Release for information. This announcement is dated 30 October 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3101400

Attachments SOLUTN-Press Release on LOA.pdf

eucoo

70sen进1.8卖。 后来又手痒1.65进， 1.28出。

icy97

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY") (i) PROPOSED DIVERSIFICATION; AND(ii) PROPOSED PRIVATE PLACEMENT(COLLECTIVELY, THE "PROPOSALS")
On behalf of the Board of Directors of SGB, M&A Securities Sdn Bhd wishes to announce that the Company proposes to undertake the following: (i) proposed diversification of the existing business of SGB and its subsidiaries (“SGB Group” or the “Group”) to include the pharmaceutical related business (“Proposed Diversification”); and (ii) proposed private placement of up to 30,732,600 new ordinary shares in SGB, representing not more than 10% of the total number of issued shares in SGB (“Proposed Private Placement”). Please refer to the attachment for further details on the Proposals. This announcement is dated 5 November 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3103016

Attachments SGB_Private placement and Diversification.pdf

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY") (i) PROPOSED DIVERSIFICATION; AND(ii) PROPOSED PRIVATE PLACEMENT(COLLECTIVELY, THE "PROPOSALS")
Unless otherwise defined in this announcement, all terms used herein shall have the same meaning as those defined in the announcement dated 5 November 2020 in relation to the Proposals (“Announcement”) Further to the Announcement, M&A Securities, on behalf of the Board, wishes to announce the following further information in relation to the Proposals as set out in the attachment below. This announcement is dated 18 November 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3105916

Attachments SGB - Additional announcement 181120.pdf

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY") (i) PROPOSED DIVERSIFICATION; AND(ii) PROPOSED PRIVATE PLACEMENT(COLLECTIVELY, THE "PROPOSALS")
Unless otherwise defined in this announcement, all terms used herein shall have the same meaning as those defined in the announcement dated 5 November 2020 in relation to the Proposals (“Announcement”) Reference is made to the Company's additional announcement dated 18 November 2020 in relation to the Proposals ("Additional Announcement"). M&A Securities, on behalf of the Board, wishes to announce the amendment to the relevant sections of the Additional Announcement. Please refer to the attachment below for further details of the amendment to the Additional Announcement. This announcement is dated 25 November 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3107760

Attachments SGB - Amended Additional announcement.pdf

SOLUTION GROUP BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Exercise of Warrants
Details of corporate proposal	Conversion of Warrants-A
No. of shares issued under this corporate proposal	5,719,800
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.2000
Par Value($$) (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	318,250,338
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 33,689,626.100
Listing Date	23 Nov 2020

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2020	30 Sep 2019	30 Sep 2020	30 Sep 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	5,288	4,873	12,209	13,670
2	Profit/(loss) before tax	577	235	322	-98
3	Profit/(loss) for the period	577	309	322	-24
4	Profit/(loss) attributable to ordinary equity holders of the parent	416	262	83	-156
5	Basic earnings/(loss) per share (Subunit)	0.14	0.09	0.03	-0.05
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1244		0.1228

SOLUTION GROUP BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Exercise of Warrants
Details of corporate proposal	Conversion of Warrants-A
No. of shares issued under this corporate proposal	4,861,800
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.2000
Par Value($$) (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	323,112,138
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 34,661,986.100
Listing Date	26 Nov 2020

SOLUTION GROUP BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY") PRIVATE PLACEMENT OF UP TO 10% OF THE TOTAL ISSUED SHARES OF SGB ("PRIVATE PLACEMENT")
No. of shares issued under this corporate proposal	30,857,600
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.9160
Par Value($$) (if applicable)	Malaysian Ringgit (MYR)   0.000
Latest issued share capital after the above corporate proposal in the following
Units	358,965,738
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 63,928,847.700
Listing Date	09 Dec 2020

Type	Announcement
Subject	OTHERS
Description	TERM SHEET BETWEEN THE MINISTRY OF HEALTH MALAYSIA ("MOH") AND SOLUTION BIOLOGICS SDN BHD ("SOLBIO"), A WHOLLY-OWNED SUBSIDIARY OF SOLUTION GROUP BERHAD ("SGB" or "THE COMPANY"), FOR THE SUPPLY OF THE COVID-19 VACCINE TO THE GOVERNMENT
INTRODUCTION The Board of Directors of Solution Group Berhad (“Board”) wishes to announce that the wholly-owned subsidiary Solution Biologics Sdn Bhd (“SOLBIO”), had on 29 January 2021 signed a Term Sheet Agreement with Government of Malaysia, represented by the Ministry of Health Malaysia (“MOH”) for the supply of the COVID-19 vaccine to the Government. The duly executed Term Sheet Agreement is to enable SOLBIO to enter into a definitive Supply Agreement to supply 3.5million doses of the Recombinant Ad5-nCoV vaccine (“Vaccine”) for the prevention of COVID-19. The Vaccine is jointly developed by CanSino Biologics Inc. (“CanSino”) and Beijing Institute of Biotechnology, Academy of Military Medical Sciences. MOH and SOLBIO hereinafter also individually referred to as “Party”, and collectively referred to as the “Parties”. INFORMATION ON CANSINO CanSino is a biotech company in the People’s Republic of China, dedicated to developing novel vaccines and therapeutics for unmet medical needs. CanSino is developing a novel recombinant Ad5-nCoV vaccine composed of an adenovirus type 5 vector (liquid for injection). SALIENT TERMS OF THE TERM SHEET AGREEMENT 1. The content of the Term Sheet Agreement represent an offer by either party to be used for preparing a definitive Supply Agreement between the parties. The Supply Agreement should be finalised and signed within 30 days after the Term Sheet Agreement is duly signed or within such extension of time as may be mutually agreed by the parties in writing. 2. The Vaccine will be delivered from SOLBIO storage facility to the Government appointed central store or logistics partner. 3. MOH to purchase 3.5 million vials of Vaccine from SOLBIO. The purchase is subject to the following milestones: i) SOLBIO obtaining the product registration and market authorization of the Vaccine in Malaysia from Drug Control Authority (“DCA”) by April 2021. ii) SOLBIO shall comply with the lot release requirement in Malaysia. iii) SOLBIO already hold Type A License under the Poison Act 1952 before the signing of the Supply Agreement. 4. MOH has the right to terminate this Term Sheet Agreement if the Purchase Milestones in Item (3) are not completed. 5. Neither of the parties may make any public announcement or disclosures regarding this term sheet or the agreement without the prior written approval of the other of the parties. FINANCIAL EFFECTS OF THE AGREEMENT i) Share capital and shareholdings of substantial shareholders The Term Sheet Agreement will not have any effect on the share capital and substantial shareholders’ shareholdings of SGB as no new SGB shares will be issued pursuant to the Term Sheet Agreement. ii) Net Assets, Net Assets per share and gearing The Term Sheet Agreement is not expected to have any material effect on the net assets, net assets per share and gearing of the Group for the financial year ending 31 December 2021. iii) Earnings and Earnings Per Share Barring any unforeseen circumstances, and subject to the execution of the definitive Supply Agreement, and subject to the Vaccine being approved by the DCA, the Term Sheet Agreement is expected to contribute positively to the future earnings and EPS of SGB for the financial year ending 31 December 2021. DIRECTORS AND MAJOR SHAREHOLDERS INTEREST None of the directors, substantial shareholders of the Company and persons connected to them has any interest, direct and/or indirect, in the Term Sheet Agreement. APPROVALS REQUIRED The Term Sheet Agreement is not subject to the approval of shareholders of the Company. SOLBIO has obtained the Type A Poison License approval on 4 February 2021. SOLBIO has to obtain the product registration and market authorization of the vaccine in Malaysia from DCA by April 2021. STATEMENT BY DIRECTORS The Board, having taken into consideration all aspects of the Term Sheet Agreement, is of the opinion that the Agreement is in the best interest of the SGB Group. This announcement is dated 4 February 2021.

icy97

Type	Announcement
Subject	OTHERS
Description	PRESS RELEASE ENTITLED "CANSINO'S COVID-19 VACCINE READY FOR BIGGER ROLLOUT TO THE PRIVATE MARKET AND AS BOOSTER SHOT"
We refer to the Company’s announcements dated 4 February 2021, 10 February 2021 and 1 April 2021. The Board of Directors of Solution Group Berhad wishes to announce that its wholly-owned subsidiary Solution Biologics Sdn Bhd (“SOLBIO”), the ASEAN manufacturing partner of CanSino Biologics Inc’s (“CanSino”) single-dose Convidecia, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (“Vaccine”), has to date completed the delivery of 2.6 million doses of the Vaccine to the Government. The remaining 300,000 and 600,000 doses are expected to be delivered in November and December 2021. SOLBIO has submitted an application to National Pharmaceutical Regulatory Agency (NPRA) to register the Vaccine as a booster shot and hope to obtain the approval in November. SOLBIO shall distribute the Vaccine to the private market, such as hospitals, clinics, the corporate and manufacturing sectors in Malaysia subject to the approval by the Ministry of Health (MOH). The Company’s Press Release entitled “CanSino’s COVID-19 vaccine ready for bigger rollout to the private market and as booster shot" is enclosed for information. This announcement dated 9 November 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3207910

Attachments Solution-PR-CanSino Covid-19 Vaccine to Private Market and Booster Shot.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2021

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2021	30 Sep 2020	30 Sep 2021	30 Sep 2020
		$$'000	$$'000	$$'000	$$'000

1	Revenue	31,777	5,288	45,911	12,209
2	Profit/(loss) before tax	3,051	577	2,725	322
3	Profit/(loss) for the period	3,051	577	1,559	322
4	Profit/(loss) attributable to ordinary equity holders of the parent	2,080	416	862	83
5	Basic earnings/(loss) per share (Subunit)	0.47	0.14	0.20	0.03
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1969		0.1940

icy97

Type	Announcement
Subject	OTHERS
Description	CANSINO'S RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR) FOR INHALATION HAS BEEN APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PEOPLE'S REPUBLIC OF CHINA
The Board of Directors of Solution Group Berhad wishes to announce that its wholly-owned subsidiary Solution Biologics Sdn Bhd (“SOLBIO”), being the ASEAN manufacturing partner of CanSino Biologics Inc (“CanSino”) is pleased to announce that CanSino’s Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (“Ad5-nCoV for Inhalation” or “Convidecia Air™”) has been proposed by the National Health Commission of the People’s Republic of China (the “PRC”) and approved by the National Medical Products Administration of the PRC (the “NMPA”) for emergency use as a booster vaccine in the PRC. Ad5-nCoV for Inhalation is a genetic engineered inhaled vaccine to prevent COVID-19 disease, it utilizing the same adenovirus vector technological platform as the intramuscular version Convidecia™, which can stimulate humoral and cellular immunity, and also induce mucosal immunity to establish the first line of defense in the respiratory tract and achieve triple comprehensive protection efficiently without intramuscular injection. Ad5-nCoV for Inhalation has unique advantages of safety, effectiveness, painlessness, convenience and availability. Convidecia Air™ is needle free which requiring only one fifth of the dosage of the intramuscular version. On 12 August 2022, SOLBIO has received the approval from Ministry of Health of Malaysia's Medical Research and Ethics Committee ("MREC") to start a clinical trial in Malaysia, marking the first trial study of the inhaled version of COVID-19 vaccine in Malaysia to test the efficacy and safety of Ad5-nCoV for Inhalation as a second booster against various COVID-19 variants. SOLBIO will be submitted an application to National Pharmaceutical Regulatory Agency (NPRA) to register Convidecia Air™ as a product. The Company’s Press Release entitled “SGB Press Release-Convidecia Air Approval By NMPA_5Sep2022 " is enclosed for information This announcement is dated 5 September 2022.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3290060

Attachments SGB Press Release-Convidecia Air Approval By NMPA_5Sep2022.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	Press Release entitled "Strategic Collaboration Accelerates: CanSino Invests in Solution Group Berhad, Fueling Advancements in Healthcare and Human Vaccine Development
Please find attached Solution Group Berhad's Press Release entitled "Strategic Collaboration Accelerates: CanSino Invests in Solution Group Berhad, Fueling Advancements in Healthcare and Human Vaccine Development”. This announcement is dated 25 August 2023.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3379903

Attachments SOLUTN-PR-Strategic Collaboration Accelerates (25.08.2023).pdf

Type	Announcement
Subject	OTHERS
Description	Press Release entitled "Strategic Collaboration Accelerates: CanSino Invests in Solution Group Berhad, Fueling Advancements in Healthcare and Human Vaccine Development
Reference is made to Solution Group Berhad's Press Release entitled "Strategic Collaboration Accelerates: CanSino Invests in Solution Group Berhad, Fueling Advancements in Healthcare and Human Vaccine Development” dated 25 August 2023. An amendment to the Press Release is made whereby the correct name of NIBM is National Institutes of Biotechnology Malaysia. This announcement is dated 18 September 2023.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3385878

Attachments PR-Strategic Collaboration Accelerates_Amendment (18.09.2023).pdf

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY")PROPOSED PRIVATE PLACEMENT OF UP TO 10% OF THE ISSUED SHARES IN SGB
On behalf of the Board of Directors of SGB, M&A Securities Sdn Bhd wishes to announce that the Company proposes to undertake a private placement of approximately 10% of the issued shares in SGB (“Proposed Private Placement”). Kindly refer to the attachment on further details of the Proposed Private Placement. This announcement is dated 25 August 2023.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3379731

Attachments SGB - Proposed Private Placement.pdf

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	SOLUTION GROUP BERHAD ("SGB" OR THE "COMPANY") PROPOSED PRIVATE PLACEMENT OF UP TO 10.0% OF THE TOTAL ISSUED ORDINARY SHARES IN SGB ("PROPOSED PRIVATE PLACEMENT")
(Unless otherwise defined, the definitions set out in the announcements dated 25 August 2023 shall apply herein) Reference is made to the earlier announcements in relation to the Proposed Private Placement dated 25 August 2023 and 29 August 2023. M&A Securities, on behalf of the Board wishes to announce additional information in relation to the Proposed Private Placement. Kindly refer to the attachment on further details of the Proposed Private Placement. This announcement is dated 20 September 2023.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3386533

Attachments SGB - Further announcement.pdf

icy97

SOLUTION GROUP BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	Private Placement of up to 10% of the issued shares in SGB
No. of shares issued under this corporate proposal	43,968,600
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.1950
Par Value($$) (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	485,587,414
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 89,322,924.900
Listing Date	03 Oct 2023

icy97

Notice of Interest Sub. S-hldr (Section 137 of CA 2016)

SOLUTION GROUP BERHAD

Particulars of Substantial Securities Holder

Name	CANSINO BIOLOGICS (HONG KONG) LIMITED
Address	Room 1901, 19/F, Lee Garden One 33 Hysan Avenue, Causeway Bay Hong Kong.
Company No.	3042973
Nationality/Country of incorporation	Hong Kong
Descriptions (Class)	Ordinary Shares
Name of registered holder	M & A NOMINEE (ASING) SDN BHD - CANSINO BIOLOGICS (HONG KONG) LIMITED
Address of registered holder	45-5, THE BOULEVARDMID VALLEY CITYLINGKARAN SYED PUTRA59200 KUALA LUMPUR

Date interest acquired & no of securities acquired
Date interest acquired	02 Oct 2023
No of securities	43,968,600
Circumstances by reason of which Securities Holder has interest	Subscription of shares via private placement
Nature of interest	Direct Interest
Total no of securities after change
Direct (units)	43,968,600
Direct (%)	9.091
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Date of notice	03 Oct 2023
Date notice received by Listed Issuer	03 Oct 2023